There are a couple of things. We're talking about elimination of backlog. By early 2009 there will be no backlog; it will be review on time. Our review-on-time timelines are 300 days.
We've also said to industry that if they brought in submissions earlier, during the early drug development phase when we are able to tell them what our requirements are, and were developing those products based on our requirements—which, by the way, would be very internationally harmonized, so we would not really be asking for any more than what any other regulator would be asking—there would be an opportunity to further decrease that timeline.
The fact that companies will be able to file a virtual submission in two or three or four countries will decrease PR costs by allowing them to use that same submission with the same data across the world.